| 李 慧,张 珏,曲文书,朱 艳,庄辉传.正元胶囊联合安罗替尼对二线治疗后进展的晚期非小细胞肺癌患者疗效、癌因性疲乏和免疫功能的影响[J].,2024,(7):1392-1395 |
| 正元胶囊联合安罗替尼对二线治疗后进展的晚期非小细胞肺癌患者疗效、癌因性疲乏和免疫功能的影响 |
| Effect of Zhengyuan Capsule Combined with Anlotinib on Efficacy, Cancer-Related Fatigue and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer after Second-Line Treatment |
| 投稿时间：2023-11-08 修订日期：2023-11-30 |
| DOI：10.13241/j.cnki.pmb.2024.07.038 |
| 中文关键词: 正元胶囊 安罗替尼 晚期非小细胞肺癌 疗效 癌因性疲乏 免疫功能 |
| 英文关键词: Zhengyuan capsule Anlotinib Advanced non-small cell lung cancer Efficacy Cancer-related fatigue Immune function |
| 基金项目:江苏自然科学基金项目（BK20211132） |
|
| 摘要点击次数: 298 |
| 全文下载次数: 204 |
| 中文摘要: |
| 摘要 目的：探讨正元胶囊联合安罗替尼对二线治疗后进展的晚期非小细胞肺癌（NSCLC）患者疗效、癌因性疲乏和免疫功能的影响。方法：选择南京大学医学院附属金陵医院2020年4月~2023年5月期间收治的103例二线治疗后进展驱动基因阴性的晚期NSCLC患者，采用随机数字表法分为对照组（接受安罗替尼治疗，n=51）和研究组（接受正元胶囊联合安罗替尼治疗，n=52）。对比两组临床疗效、Piper疲乏量表、Karnofsky功能状态评分（KPS）、血清肿瘤标志物[细胞角蛋白19片段抗原21-1（CYFRA21-1）、癌胚抗原（CEA）、糖类抗原125（CA125）]、免疫功能指标[自然杀伤（NK）细胞、T淋巴细胞亚群：CD4+、CD8+、CD4+/CD8+]，同时观察两组治疗期间不良反应发生情况。结果：相较于对照组，研究组的客观缓解率（ORR）、疾病控制率（DCR）更高（P<0.05）。研究组治疗后Piper疲乏量表评分低于对照组，KPS评分高于对照组，血清肿瘤标志物CYFRA21-1、CEA、CA125下降水平高于对照组，免疫功能指标NK细胞、CD4+、CD4+/CD8+下降幅度小于对照组，CD8+升高幅度小于对照组（P<0.05）。两组治疗期间各不良反应发生率组间对比未见差异（P>0.05）。结论：正元胶囊联合安罗替尼可提高二线治疗后进展驱动基因阴性的晚期NSCLC患者的临床疗效，可降低肿瘤标志物水平，减轻癌因性疲乏，改善生活质量，提高免疫功能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of zhengyuan capsule combine with anlotinib on efficacy, cancer-related fatigue and immune function in patients with advanced non-small cell lung cancer (NSCLC) after second-line treatment. Methods: 103 patients with advanced NSCLC who were progressed driver gene negative after second-line treatment in Jinling Hospital Affiliated to Medical School of Nanjing University from April 2020 to May 2023 were selected, and patients were divided into control group (treated with anlotinib, n=51) and study group (treated with zhengyuan capsules combine with anlotinib, n=52) by random number table method. The clinical efficacy, Piper fatigue scale, Karnofsky functional status score (KPS), serum tumor markers [cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125)], immune function indicators [natural killer (NK) cells, T lymphocyte subsets: CD4+, CD8+, CD4+/CD8+] were compared between two groups, and the occurrence of adverse reactions during the treatment in two groups was observed. Results: Compared with control group, the objective response rate (ORR) and disease control rate (DCR) in study group were higher (P<0.05). The Piper fatigue scale score in study group after treatment was lower than that in control group, KPS score was higher than that in control group. The decrease levels of serum tumor markers CYFRA21-1, CEA, and CA125 in study group were higher than those in control group (P<0.05), immune function indicators，the decrease rate of NK cells, CD4+, CD4+/CD8+ in study group was lower than those in control group, and the increase rate of CD8+ was lower than that in control group (P<0.05). There was no difference in the incidence of adverse reactions between two groups during treatment (P>0.05). Conclusion: Zhenyuan capsule combine with anlotinib can improve the clinical efficacy of advanced NSCLC patients with progression driver gene negative after second-line treatment, which can reducing the level of tumor markers, reducing cancer-related fatigue, improving quality of life and improving immune function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
